Prestige Biopharma Ltd. (950210)

Overview

Prestige BioPharma Limited is a prominent biopharmaceutical company focused on advancing the healthcare industry through its intensive research and development efforts. Since its inception in 2015, the company has dedicated itself to the marketing and development of biosimilars, innovative first-in-class antibody drugs, and preventive vaccines. With its headquarters stationed in Singapore, Prestige BioPharma has carved a niche in the global pharmaceutical landscape, pioneering efforts to bring forth affordable and effective therapeutic and diagnostic solutions for life-threatening diseases, enhancing patient care and outcomes.

Products and Services

• Biosimilars

  At its core, Prestige BioPharma is deeply involved in the development of biosimilars, which are biotherapeutic products highly similar to already approved reference products. Notably, its portfolio includes:

  • Trastuzumab - Currently under regulatory review, Trastuzumab is being developed for the treatment of HER2-positive breast and gastric cancers, offering hope to patients with these aggressive forms of cancer.
  • Bevacizumab - In a phase 3 clinical study, Bevacizumab is aimed at treating solid tumours, demonstrating the company's commitment to addressing a wide array of cancer types.
  • Adalimumab - With a phase 1 clinical study ongoing, Adalimumab is being explored for its efficacy in treating arthritis, reflecting the company's dedication to combating inflammatory and autoimmune conditions.
• First-in-Class Antibody Therapeutics

  Prestige BioPharma is breaking new ground in the development of first-in-class antibody therapeutics. This includes:

  • Monoclonal Antibodies - Tailored for specific targets, these antibodies are designed to treat a variety of life-threatening diseases.
  • Bispecific Antibodies - Innovative treatments that can bind to two different antigens simultaneously, offering novel approaches to cancer therapy.
  • Fusion Antibodies - Combining different functionalities into a single molecule, these antibodies represent a cutting-edge frontier in targeted therapeutics.
• Vaccines for COVID-19

  The company is also actively involved in the development of vaccines to combat the COVID-19 pandemic, contributing to the global efforts to control and reduce the spread of the virus.

• Diagnostic Kits

  Further diversifying its product range, Prestige BioPharma has ventured into the development of diagnostic kits, with a particular focus on detecting pancreatic adenocarcinoma upregulated factor. This initiative is pivotal in early cancer detection, potentially improving patient survival rates through timely intervention.